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Background/aim: Quantification of oral mucositis that progresses during concomitant chemo-radiotherapy (CCRT) is essential for its
management. It is important to determine the methods that are simple, reliable and beneficial in foreseeing mucositis at earlier stages
of treatment.
Materials and methods: A prospective study was conducted on 100 oral cancer patients receiving CCRT following the inclusion criteria.
Patients were evaluated for mucositis i.e. erythema and ulcers by using the World Health Organization (WHO) scale and the oral
mucositis assessment scale (OMAS), whereas mature and immature cells were identified by exfoliative cytology. Clinical examination
and procedure of oral cavity were performed before, on days 5, 17, and at the end of treatment.
Results: Oral mucositis was observed in all oral squamous cell carcinoma (OSCC) patients receiving CCRT on different days with
noteworthy increase from day 5 of CCRT to the end of treatment. For OMAS grading related to ulceration and erythema, Grade 1
(7.2%; 34%) was most commonly seen on the 5th day of CCRT, Grade 2 (29%; 19%) and Grade 3 (19%) were most frequently seen at the
17th day and end of CCRT, accordingly. With respect to WHO scale grades 1 and 2 (18.3%; 21.5%) was most frequently observed at the
17th day of CCRT, whereas grades 3 and 4 (12.5%; 2%) was noted at the end of CCRT. There was statistically significant increase in the
percentage of immature cells at the end of CCRT (99%). A significant association (P < 0.0000) was observed among the days of smear
and maturation stages of epithelial cells as well as among WHO mucositis grading, OMAS and types of epithelial cells, respectively.
Conclusion: According to the findings of the study, oral mucositis grade is directly proportional to the progressing days of CCRT. Oral
mucositis is frequently related to adverse clinical outcomes, affecting the patient’s quality of life. It is essential to develop methods that
can be employed for the assessment of CCRT associated oral mucositis.
Key words: Oral cancer, oral mucositis, CCRT, OMAS scale, exfoliative cytology

1. Introduction
Oral mucositis, also known as stomatitis, is a usual, doselimiting and possibly incapacitating complication of
concomitant chemo-radiotherapy (CCRT) appearing
in more than 90% of head and neck cancer patients
[1]. It can either be caused by the systemic effects
of chemotherapeutic drugs or as a result of direct
damage to the oral mucosa in radiotherapy [2].
Aggressive regimens are now considered to be an effective
method to arrest the tumour growth and increase the
chances of survival of advanced head and neck cancer
patients, leading to further possible complications [3]. These
treatments unfortunately do not exclusively target neoplastic
cells, but also equally affect the cellular homeostasis of

normal host cells. This leads to disturbances in the function
of many different cells, among which is also the actively
dividing epithelial cells of the oral cavity [4]. The loss of
these epithelial cells results in mucositis, which is manifested
as mucosal atrophy, necrosis and ulceration, thus causing
pain, difficulty in chewing and swallowing [5,6]. This fragile
oral mucosa, when augmented with reduced immunity, puts
patients at high risk of opportunistic infections in the mouth.
Mucositis may also extend and involve the gingivae and
teeth of the patients, raising hygiene, aesthetic and speech
concerns. All of this collectively affects patients’ confidence,
as well as quality of life [7].
Mucositis induced by CCRT is a dose-regulated and
expensive side effect [8]. Mucositis starts to occur as

* Correspondence: drkashifazam@gmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

675

MINHAS et al. / Turk J Med Sci
early as 5 to 10 days after the start of treatment as a result
of direct radiation or indirectly due to drug-induced
neutropenia causing mucositis [9,10]. The extent of acute
toxicity produced by CCRT is considerably higher than the
radiotherapy or chemotherapy alone due to intensified local
host tissue response [1,9]. Mucositis is acknowledged as the
principal limiting factor for further treatment intensification
in such situations [11]. With the advent of the latest agents
being used in combination with radiotherapy, reports
of frequent interactions like mucositis are evident in the
literature [12].
The first ever method used to determine the effects of
radiotherapy on oral mucosa among oral cancer patients was
cytologic evaluation, which was reported in 1959 [13,14].
Frequently used scales, based on clinical examination to
assess mucositis in CCRT patients, are the World Health
Organization (WHO) scale, the National Cancer Institute
Common Toxicity Criteria (NCI-CTC), the oral mucositis
assessment scale (OMAS) and the Radiation Therapy
Oncology Group (RTOG) [4]. All of the mentioned scales
primarily assess the oral mucosa for clinical changes, such
as erythema and ulceration, and ascribe a score depending
on these signs [15]. A commonly used basic scale is the
WHO scale, which comprises both objective and subjective
measures to determine oral mucositis [16], while the OMAS
primarily considers erythema and ulceration at nine different
sites around the oral cavity to give a grade for objective
measurement. [17]. Therefore, calculating the mature oral
epithelial cell percentage in oral smears may be an objective
parameter to analyse the consequence of CCRT [4].
Hence, the purpose of this study is the quantification
of oral mucositis that progresses during CCRT at the
clinical as well as cellular level. In this study, the epithelial
cells in oral mucosa will be studied for their viability while
comparing them with clinical World Health Organization
(WHO) grading and the OMAS assessment scale on the
specific days of CCRT. This study also aims to determine
the efficacy of the method used, in foreseeing mucositis at
earlier stages of CCRT when compared with the WHO and
OMAS clinical scoring, which are the current methods in
practice.
2. Material and methods
2.1. Study design and sample characteristics
This was a prospective study, conducted at the Institute of
Nuclear Medicine & Oncology Lahore (INMOL), which
is an oncology care centre for patients with cancers.
Data and samples were collected from the oral squamous
cell carcinoma patients presenting for CCRT. The study
recruitment period ended when 100 participants had
been enrolled as the sample size was calculated with 95%
confidence interval by the given formula:
n = Z21-α/2 P (1-P)d2 .
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2.2. Participants
Possibly suitable patients were informed in detail about
the ongoing study. A total of 100 patients having oral
squamous cell carcinoma (OSCC) were selected for the
present study and followed up throughout the course
of treatment i.e. CCRT. Patients ≥ 18 years old and
undergoing CCRT as a treatment option for the first time,
patients of both genders and histologically diagnosed with
squamous cell carcinoma found at one of the following
sites − soft palate, tongue, oropharynx, buccal mucosa,
retromolar trigone and floor of mouth were included in
the present study. Excluded from the current study were
participants who: had previously undergone CCRT; were
only on radiotherapy or chemotherapy alone; had received
treatment with antibiotics in the 2-week period earlier in
the initiation of the treatment; had acute periodontitis or
oral candidiasis; had a naso-gastric tube at the initiation
of the treatment; and patients with immunocompromised
conditions such as diabetes, HIV, etc.
Radiotherapy was delivered by the use of intensitymodulated radiotherapy treatment (IMRT) and with the
use of new fractionation schedules i.e. with concomitant
boost and hyperfractionation. Patients who receive
IMRT characteristically get one fractionation daily. The
patients were planned to receive a total dose of at least
70–119 Gy of radiotherapy given by means of an external
beam technique that was evaluated over 7 weeks (1.8–2
Gy/day for 5 days/week). All the targets were receiving
the same fraction and dose of radiations i.e. 50−54 Gy,
whereby the margins were distinctly enhanced either with
concomitant boost or consecutive fractionation schedules.
The chemotherapy drug cisplatin and 5-fluorouracil were
administered depending on the stage of the tumour [18].
For the study group, clinical procedures were conducted
on the first day before the start of CCRT, then the next
clinical procedure was done on day 5 of treatment, on day
17 of treatment (the midpoint of treatment) and at the
end of treatment (CCRT). For the healthy control groups
samples were only collected on the first day.
The subjects in the control group were age- and gendermatched and consisted of 30 normal healthy persons (15
male/15 female) who were routinely well, had no addictive
habits and were not taking any medication.
2.3. Data collection
The demographic records were examined by a trained
researcher who gathered data on the following variables,
using the designed proforma: age; sex; histological type
of malignancy; location of tumour; stage of tumour;
history of alcohol and tobacco use; radiation dose; and
chemotherapy drug.
2.4. Clinical oral examination
Clinical signs of oral mucositis were noted by means of
WHO grading and the OMAS, which are possibly the
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tools most frequently utilized by clinicians throughout the
world.
Patients who were undergoing CCRT were clinically
evaluated for mucositis and scoring was done on the basis
of the WHO scale [4] (Table 1). For grading, the buccal
mucosa on the treated side and those areas which were
included in the radiation therapy were assessed for the
mucositis grading.
2.5. Oral mucositis assessment scale
To obtain OMAS ulceration and erythema scores
(total OMAS scores of ulceration/number of sites with
ulceration), the nine oral cavity assessed sites were ventral
and bilateral tongue, soft and hard palate, upper and lower
lip, left and right buccal mucosa and floor of mouth.
The erythema is evaluated using a 3-point scale as
follows: 0 = none (no change in the colour of the mucosa);
1 = mild/moderate (increase in intensity of colour of
mucosa) and 2 = severe (mucosa is the colour of fresh
blood).
The OMAS ulceration scoring criteria were as follows:
Grade 0 = no lesion; Grade 1 = <1 cm2; Grade 2 = 1–3
2
cm ; Grade 3 = >3 cm2.
The value of the OMAS on the respective days of
CCRT (before, days 5, 17 and end of CCRT) is obtained by
summing the erythema and ulceration scores at each site.
2.6. Buccal smear
Before taking buccal smears, every subject was asked to
rinse their oral cavity with normal saline. Smears were
obtained from the representative sites of buccal mucosa,
which were in the field of exposure for the irradiation of
malignant tumours and were expected to develop oral
mucositis during the CCRT. These smears were taken on
respective days of treatment i.e. before the exposure to
CCRT, on the 5th day after first exposure to CCRT, on the
17th day of CCRT (the mid-point of therapy) and at 7th
week (end of treatment). A wooden spatula was scraped
firmly on the buccal mucosa, scrapings were transferred
carefully onto frosted glass slides, fixed using alcohol and
later stained with Papanicolaou (PAP) stain. A total of four
slides were made from each subject on each respective
day of sampling and were labeled carefully. Under a
light microscope the epithelial cell differentiation and
morphology were studied. Epithelial cells were graded as
listed in Table 2 [19].
2.7. Statistical analysis
The data were entered and analysed using descriptive
statistics with the aid of the Statistical Package for the
Social Sciences (SPSS, version 22.0, IBM Corporation,
Armonk, NY, USA). Mean + standard deviation (SD)
values were given for quantitative variable like age.
Frequencies, percentages and graphs were given for
qualitative variables such as oral mucositis grading and

Table 1. WHO grading for oral mucositis.
Grade

Description

Grade 0 (none)

No change

Grade 1 (mild)

Soreness/erythema

Grade 2 (moderate)

Erythema/ ulcers/ can eat solids

Grade 3 (severe)

Ulcers/ requires liquid diet only

Grade 4 (life threatening)

Alimentation not possible

Table 2. Maturation stages of epithelial cells on the basis of
differentiation and morphology.
Color of epithelial cells

Type of epithelial cells

Orange-stained cells

Mature

Blue/green stained cells

Immature

Partly orange and partly green

Intermediate maturation

epithelial cell keratinization. The data was analyzed by
applying the chi-square test and Fisher’s exact tests, and
was considered significant if P < 0.05.
3. Results
All patients in this study presented with oral mucositis
during the treatment of oral cancers with CCRT, which
in a few patients appeared as erythema after a dose of
approximately 10 Gy and increased afterwards with a
boosted absorption of therapeutic chemo-radiation doses
throughout the course of treatment.
Gender distribution showed that males (62%) were
predominant with a male: female ratio of 1.6:1. The
patients’ ages ranged from 27 to 80 years with a mean age
of 50.21 ± ( SD: 10.647 ). The main stream of patients
presented with OSCC involving the tongue (n = 55; 55%)
(Figure 1). A majority of the patients presented with the
addictive habit of smoking (39%) whereas 39% of patients
had no addictive habits. Clinical examination of their oral
hygiene revealed that an overwhelming number of patients
had poor oral hygiene (51%).
When the OSCC was sub-classified on the basis of
their histological subtypes, it was observed that among 100
cases, the majority (98%) were conventional SCC while
verrucous carcinoma was seen in only n = 2 (2%) cases.
The most common histological grade was moderately
differentiated OSCC seen in n = 50 (50%) cases. Similarly,
the present study showed that majority of patients receiving
CCRT presented with advanced tumour T4 stage (59%).
Considering the fractions of radiotherapy dosages,
patients received 70 Gy, 90 Gy and 119 Gy. Half of the
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Figure 1. Pie chart showing site distribution of oral squamous
cell carcinoma in the study population.

patients (50%) received 90 Gy dose of radiotherapy.
Similarly, while considering the chemotherapeutic drugs,
most of the patients n = 80 (80%) received combination
drug therapy (cisplatin and 5-fluorouracil). Table 3
displays the demographic and clinical characteristics of
the patients.
All 100 patients who underwent the CCRT treatment
had different grading of oral mucosal reaction according
to the WHO grading scale and OMAS scale, which were
applied to all patients from the first day of the study i.e.
first admission for CCRT and followed up till the end
of treatment. As the study progressed, the response rate
increased from the 17th day until the end of treatment.
Oral mucositis was observed in all OSCC patients (n
= 400) on four different days of CCRT, whereas in control
group n = 30 no such changes was observed. According
to WHO grading, grade 2 was most commonly seen in
n = 86 (21.5%), followed by grade 1 in n = 73 (18.3%),
grade 3 in n = 50 (12.5%) and grade 4 in n = 8 (2%). When
we compared the WHO oral mucositis grading with the
days of treatment, grade 2 was most commonly seen at
the mid-point of treatment n = 47 (54.7%), whereas grade
3 and grade 4 were most frequently observed at the end
of treatment n = 44 (88%) and n = 8 (100%), accordingly
(Figure 2).
For OMAS, the most frequent grade for ulceration
observed in the present study was grade 2 n = 116 (29%),
followed by grade 3 n = 77 (19%) and grade 1 n = 29 (7.2%);
however no lesions were seen in 44.5%, whereas the most
frequently noted grade for erythema according to OMAS
was grade 1 (34%), followed by grade 2 (19%) and grade
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0 (47%), respectively. When we compared OMAS during
days of treatment it was noticed that grade 1 was most
frequently seen at the 5th day of treatment n = 20 (69%).
However, grades 2 and 3 were most commonly reported
on the 17th day of CCRT n = 88 (75.9%) and at the end of
treatment n = 72 (93.5%), respectively. However, no such
findings were seen in the control group.
When oral mucositis WHO grading and the OMAS
scale were compared from day one to the last day of
treatment it was noticed that there was a significant rise
in the severity and incidence of oral mucositis grading,
starting from day 5. A severe type of oral mucositis was
developed by the end of treatment, whereas in the middle
of the treatment the patients exhibited grade 3, according
to WHO, and grade 2, according to OMAS, and none of
the patients had grade 0, according to both gradings. By
applying a chi-square test, the percentages of WHO grades
on different therapy days were significantly different
P-value (< 0.0000) and total OMAS scores on different
therapy days were significantly different, too (P < 0.0000)
(Figure 3). A significant association was also seen between
the WHO oral mucositis grading and the age of patient
(P < 0.000). Though no statistically significant association
was seen among WHO, OMAS and clinical variables but
it was noticed that the oral mucositis was higher among
males n = 62 (62%) for the WHO grading and the OMAS
scale, accordingly.
Out of 400 total smears from 100 patients on different
days of CCRT, mature epithelial cells were seen in n =
200 (50%) of smears (Figure 4), whereas intermediate
and immature cells were seen in n = 65 (16.3%) and n =
135 (33.8%) (Figures 5 and 6). Whereas in control group,
normal cells (large blue, blue-red & red-yellow) were
observed on exfoliative cytology. There was statistically
significant increase in the percentage of immature cells
from the 17th day to the end of CCRT treatment. Among
the days of smears, intermediate epithelial cells (64%) were
predominantly observed at the 17th day of CCRT, with
95% confidence interval: 2.98−3.04, immature epithelial
cells (99%) were most frequently seen at the end of CCRT
with 95% confidence interval: 3.65−3.80, whereas mature
epithelial cells (100%) were mostly seen before and at the
5th day of CCRT with 95% confidence interval: 1.43−1.56,
accordingly. By applying the chi-square test, a significant
association (P < 0.0000) was observed among the days of
smear and types of epithelial cells (immature, intermediate
and mature) and a significant decrease in the percentage of
mature epithelial cells was observed from the start to end
of CCRT. In addition, a statistically significant association
was seen among WHO mucositis grading and types of
epithelial cells, also the same findings were observed
between OMAS and types of epithelial cells respectively
(P < 0.000).
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Table 3. Clinical characteristics of patients of oral squamous cell carcinoma from the INMOL hospital in
Lahore (n = 100).
Variable

Value

Confidence interval (95%)

Age
25−35

n = 11 (11%)

36−45

n = 22 (22%)

46−55

n = 44 (44%)

56−65

n = 14 (14%)

65−75

n = 8 (8%)

76−85

n = 1 (1%)

2.67–3.10

Sex
Male

n = 62 (62%)

Female

n = 38 (38%)

1.28–1.47

Site
Lip

n = 2 (2%)

Buccal mucosa

n = 29 (29%)

Tongue

n = 55 (55%)

Palate

n = 3 (3%)

Floor of mouth

n = 1 (1%)

Base of tongue

n = 8 (8%)

Retromolar area

n = 2 (2%)

2.79–3.28

Addictive habits
Smoking

n =37 (37%)

Pan/betel nut + quid

n = 10 (10%)

Wet snuff/naswar

n = 1 (1%)

Smoking + pan/betel nut + quid

n = 13 (13%)

No history

n = 39 (39%)

3.55–4.66

Oral hygiene
Good

n = 5 (5%)

Moderate

n = 44 (44%)

Poor

N = 51 (51%)

2.34–2.577

Histological grading
Well differentiated squamous cell carcinoma

n = 33 (33%)

Moderately differentiated squamous cell carcinoma

n = 50 (50%)

Poorly differentiated squamous cell carcinoma

n = 15 (15%)

Verrucous carcinoma

n = 2 (2%)

1.71–2.006

Clinical staging
T2

n = 15 (15%)

T3

n = 26 (26%)

T4

n = 59 (59%)

3.29–3.58

Surgical treatment
Yes

n = 21 (21%)

No

n = 79 (79%)

1.70–1.87

Radiotherapy dosage
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Table 3. (Continued).
70 Gy

n = 31 (31%)

90 Gy

n = 50 (50%)

119 Gy

n =19 (19%)

1.74−2.0

Chemotherapy drugs
Cisplatin

n = 20 (20%)

Cisplatin + fluorouracil

n = 80 (80%)

2.44–2.75

Figure 2. Patient showing WHO and OMAS grade 3 oral mucositis at the end of
treatment.

4. Discussion
In the present study, it was observed that oral mucositis is
predominantly seen in male patients (62%) with a mean
age of 50.21, which was in accordance with the study
conducted by Igor et al. in 2019 where the mean age was 55
± 14 years and the prevalence of oral mucositis was higher
among males (78.2%) [20]. Previous researchers also
found a higher occurrence of oral mucositis in the male
population, with approximately 89% and 60%, respectively
[21,22]. The greater occurrence in the male population
can be described by more incidences of injurious habits
ascribed to this gender, such as smoking, use of alcohol,
poor hygiene as well as a less frequent visit to dental
practitioners [23].
A study carried out in the United States revealed that
head and neck tumour patients who received CCRT or
cumulative radiation doses of 5000 cGy, are more likely to
develop oral mucositis. The finding of that study is similar
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to the present study [24]. A study conducted in Italy
reported that in patients with head and neck cancers, oral
mucositis was commonly seen because of the proximity of
the oral mucosa to the field of radiation [25]. Furthermore,
an association was established between the prevalence of
oral mucositis and increased doses of radiation, which
is comparable to statistics described in current study. A
literature research revealed many similar findings that are
in accordance with the present study [26,27].
The OMAS scoring system primarily relies on the
measurement of alteration in the oral mucosa (erythema,
ulceration). Although the OMAS scale is basic and simple,
it requires more time to assess oral mucositis [15,28]. In
the current study, based on the OMAS scoring system
related to ulceration, the most frequently recorded grade
was grade 2 appearing at the end of CCRT. This was in
accordance with the study conducted in paediatric cancer
patients receiving chemotherapy, which reported that the
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Figure 3. Showing association between WHO oral mucositis grading
and days of test/treatment.

Figure 4. Mature epithelial cells before CCRT stained with PAP (10 ×).

median maximum site score of OMAS was 1 (interquartile
range IQR 0, 2). Moreover, significant correlation was
observed between the OMAS and WHO scales which are
in concordance with the study conducted in Canada [29].
The validity of OMAS in adults receiving chemotherapy

for cancer is well documented. Although OMAS and
WHO both appear to be valid, literature reviews have
highlighted that the subjective WHO and objective OMAS
are delivering different knowledge and it may be significant
for future clinical studies to include both scales together.
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Figure 5. Intermediate and mature cells at the 17th day of CCRT (10 ×).

Figure 6. Immature epithelial cells with marked inflammation at the end of CCRT (10 ×).

To overcome the drawbacks of the clinical scoring
system, the in vitro assay was also used in the present study.
There is increased desquamation of oral epithelial cells
as a result of a high dose of radio and chemotherapeutic
drugs. In this study, there was statistically significant
increase in the percentage of immature cells from the
17th day to the end of CCRT. A statistically significant
association was seen between the days of CCRT and
type of epithelial cells (P < 0.000), thus suggesting that
as CCRT session progressed, the percentage of epithelial
viable cells also increased, which was in accordance with
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the study conducted by Nagarajan stating that the mature
cells and immature epithelial cells showed statistically
significant decrease and increase (P < 0.0005) from
the 2nd week to the 4th week of chemo-radiotherapy,
respectively.
A statistically significant association among the WHO
mucositis grading, OMAS and types of epithelial cells (P <
0.000) was also noticed in this study, which was in contrast
with the study conducted by Nagarajan showing that in
the 2nd week there was a significant rise in viable cells
compared to the WHO score [30].
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5. Conclusion
The present study’s results reveal a significant association
among the evaluation of the CCRT-induced oral mucositis,
using the WHO, OMAS scale and in vitro assessment
in patients with advanced oral cancer. All of these are
valuable means for enhancing the clinical evaluation of oral
mucositis. For those patients where oral examination is not
possible, the WHO and OMAS scales can be implemented
in such conditions.
The oral mucositis can be critical with the progression of
CCRT, affecting the quality of life and interfering with CCRT

treatment as well. It is suggested that multidisciplinary
teams and patients must discuss the severity and onset of
CCRT-induced oral mucositis therefore providing the best
supportive care to patients suffering from CCRT- induced
oral mucositis.
Informed consent
This study has been approved by the Advanced Studies &
Research Board (ASRB) of the University of Health Sciences,
Lahore and written informed consent was obtained from all
study participants before the start of the clinical procedure.
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